RNA结合蛋白LRPPRC促进癌症对CDK46抑制剂的耐药性

核心信息

• 论文英文标题: The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
• 期刊: Nat Commun
• 发表年份: 2023
• DOI: 10.1038/s41467-023-39854-y
• PMID/PMCID: 37452037; PMC10349134

研究概览

Our study reveals a mechanism responsible for CDK4/6i resistance and provides an enlightening approach to investigating the combinations of CDK4/6 and LRPPRC inhibitors in cancer therapy. However, their effects are limited by primary or acquired resistance in virtually all tumor types.

核心发现

Kinase inhibitors against Cyclin Dependent Kinase 4 and 6 (CDK4/6i) are promising cancer therapeutic drugs.

However, their effects are limited by primary or acquired resistance in virtually all tumor types.

Here, we demonstrate that Leucine Rich Pentatricopeptide Repeat Containing (LRPPRC) controls CDK4/6i response in lung cancer by forming a feedback loop with CDK6.

LRPPRC binds to CDK6-mRNA, increasing the stability and expression of CDK6.

Echo Biotech 角色

客户pull down RNA微量长链建库测序分析

关联平台: Exoomics®

关联服务与能力: EV lncRNA/mRNA Sequencing

关联产品或试剂: 无明确产品引用

参考文献

原始论文: The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer Nat Commun. 2023. DOI: 10.1038/s41467-023-39854-y. PMID/PMCID: 37452037; PMC10349134.